Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Sponsor: Janssen Research & Development, LLC
The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.
This description comes directly from the study's public registry record.
Study Contact · 844-434-4210 · Participate-In-This-Study1@its.jnj.com
Always discuss trial participation with your own doctor first.
| IMMUNOe Health and Research Centers | Centennial, Colorado, United States | Recruiting |
| Healthcare Innovations Institute Inc | Coral Springs, Florida, United States | Recruiting |
| Neurology Associates PA | Maitland, Florida, United States | Completed |
| ALS Center at the University of Miami | Miami, Florida, United States | Recruiting |
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| Johns Hopkins Hospital | Baltimore, Maryland, United States | Recruiting |
| Boston Clinical Trials | Boston, Massachusetts, United States | Completed |
| Beaumont Hospital Royal Oak | Royal Oak, Michigan, United States | Completed |
| Kansas City Veterans Affairs Medical Center | Kansas City, Missouri, United States | Recruiting |
| The Neurological Institute of New York | New York, New York, United States | Completed |
| South Shore Neurologic Associates - Patchogue | Patchogue, New York, United States | Recruiting |
| The Neurological Institute, PA | Charlotte, North Carolina, United States | Recruiting |
+ 106 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05327114